Endocrine Abstracts

Non-alcoholic fatty liver disease (NAFLD) is gaining increasing recognition as a component of the epidemic of obesity worldwide. The spectrum of NAFLD ranges from simple fatty liver with benign prognosis, to a potentially progressive form, non-alcoholic steatohepatitis (NASH), which may lead to liver fibrosis and cirrhosis, resulting in increased morbidity and mortality. All features of the metabolic syndrome, including obesity, type 2 diabetes, arterial hypertension, and hype...